|
Market Closed -
NSE India S.E.
15:05:07 11/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 390.65 INR | -0.26% |
|
-1.70% | -0.83% |
| 09-09 | Indian shares eye muted start as oil climbs on intensifying Mideast tensions | RE |
| 09-08 | Biocon Limited Secures 10-Year Supply Contract for Pertuzumab in Brazil with Bahiafarma and Bionovis | CI |
| Market Cap | 633B 6.62B 5.71B 5.4B 4.9B 9.19B 9.23B 64.17B 24.67B 322B 24.87B 24.32B 1,017B | P/E 2027 * |
56.2x | P/E 2028 * | 33.6x |
|---|---|---|---|---|---|
| Enterprise Value | 735B 7.7B 6.63B 6.28B 5.69B 10.68B 10.73B 74.58B 28.68B 374B 28.91B 28.27B 1,182B | EV / Sales 2027 * |
3.79x | EV / Sales 2028 * | 3.25x |
| Free-Float |
51.84% | Yield 2027 * |
0.15% | Yield 2028 * | 0.24% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| BIOCON | Delayed | |
Bombay S.E.
| BIOCON | Delayed |
Last Transcript : Biocon Limited
| 1 day | -0.26% | ||
| 1 week | -1.70% | ||
| Current month | -5.18% | ||
| 1 month | -8.60% | ||
| 3 months | -6.77% | ||
| 6 months | -0.40% | ||
| Current year | -0.83% |
| 1 week | 384.65 |  | 403.95 |
| 1 month | 384.65 | | 421.6 |
| Current year | 337.7 | | 447.15 |
| 1 year | 337.05 | | 447.15 |
| 3 years | 217.5 | | 447.15 |
| 5 years | 191.55 | | 447.15 |
| 10 years | 134.07 | | 487.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Saurabh Paliwal
IRC | Investor Relations Contact | - | - |
Shreehas Tambe
CEO | Chief Executive Officer | - | 01/04/2026 |
Kedar Upadhye
DFI | Director of Finance/CFO | 48 | 01/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 24/04/2014 | |
| Director/Board Member | 71 | 01/01/2000 | |
| Chairman | 73 | 29/11/1978 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.26% | -1.70% | +6.97% | +46.15% | 6.62B | |
| -2.11% | -1.68% | +43.40% | +95.27% | 66.93B | |
| -0.23% | -4.45% | +32.50% | +75.75% | 61.97B | |
| +1.67% | +2.47% | -11.32% | +380.54% | 28.26B | |
| -1.05% | -4.43% | +28.84% | +10.59% | 24.59B | |
| +0.34% | -6.78% | -0.01% | -16.35% | 24.3B | |
| +0.43% | -3.37% | +16.22% | -17.99% | 19.41B | |
| -3.03% | -2.29% | +181.72% | +335.27% | 16.77B | |
| -1.94% | -4.94% | -8.15% | +483.69% | 14.18B | |
| +3.24% | -0.31% | -7.34% | +880.45% | 14B | |
| Average | -0.29% | -2.82% | +28.28% | +227.34% | 27.7B | |
| Weighted average by Cap. | -0.55% | -2.80% | +30.67% | +167.68% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 194B 2.03B 1.75B 1.66B 1.5B 2.82B 2.83B 19.7B 7.57B 98.81B 7.64B 7.47B 312B | 223B 2.33B 2.01B 1.9B 1.73B 3.24B 3.25B 22.6B 8.69B 113B 8.76B 8.57B 358B |
| Net income | 11.09B 116M 100M 94.7M 85.83M 161M 162M 1.12B 432M 5.64B 436M 426M 17.83B | 17.45B 183M 157M 149M 135M 253M 255M 1.77B 681M 8.88B 686M 671M 28.06B |
| Net Debt | 103B 1.07B 926M 877M 795M 1.49B 1.5B 10.42B 4.01B 52.25B 4.04B 3.95B 165B | 91.52B 958M 825M 782M 708M 1.33B 1.34B 9.28B 3.57B 46.56B 3.6B 3.52B 147B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | ₹390.65 | -0.26% | 3,665,623 |
| 10/09/26 | ₹391.65 | -0.85% | 4,737,510 |
| 09/09/26 | ₹395.00 | +0.69% | 10,271,402 |
| 08/09/26 | ₹392.30 | +0.23% | 2,791,301 |
| 07/09/26 | ₹391.40 | -1.51% | 2,488,189 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIOCON Stock
Select your edition
All financial news and data tailored to specific country editions
